Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49


PET Assessment of Epicardial Intimal Disease and Microvascular Dysfunction in Cardiac Allograft Vasculopathy.

Chih S, Chong AY, Erthal F, deKemp RA, Davies RA, Stadnick E, So DY, Overgaard C, Wells G, Mielniczuk LM, Beanlands RSB.

J Am Coll Cardiol. 2018 Apr 3;71(13):1444-1456. doi: 10.1016/j.jacc.2018.01.062.


2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.

Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel G, Robinson SD, Sibbald M, So DY, Wong GC, Abunassar JG, Ackman ML, Bell AD, Cartier R, Douketis JD, Lawler PR, McMurtry MS, Udell JA, van Diepen S, Verma S, Mancini GBJ, Cairns JA, Tanguay JF; members of the Secondary Panel.

Can J Cardiol. 2018 Mar;34(3):214-233. doi: 10.1016/j.cjca.2017.12.012. Epub 2017 Dec 19. Review.


Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery.

Russo JJ, James TE, Ruel M, Dupuis JY, Singh K, Goubran D, Malhotra N, Rubens F, Chong AY, Hibbert B, Boland P, Tran DT, Tanguay JF, Lordkipanidzé M, Perrault L, Wells GA, Bourke M, Chan V, So DY; CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators.

Eur Heart J Acute Cardiovasc Care. 2018 Jan 1:2048872617740832. doi: 10.1177/2048872617740832. [Epub ahead of print]


International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.

Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ.

Circulation. 2017 Nov 14;136(20):1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164. Epub 2017 Oct 30. Review.


Incidence, predictors, and clinical outcomes of early stent thrombosis in acute myocardial infarction patients treated with primary percutaneous coronary angioplasty (insights from the University of Ottawa Heart Institute STEMI registry).

Singh K, Rashid M, So DY, Glover CA, Froeschl M, Hibbert B, Chong AY, Dick A, Labinaz M, Le May M.

Catheter Cardiovasc Interv. 2018 Apr 1;91(5):842-848. doi: 10.1002/ccd.27215. Epub 2017 Jul 22.


P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.

So DYF, Bagai A, Tran U, Verma S, Mehta SR.

Curr Opin Cardiol. 2017 Sep;32(5):617-626. doi: 10.1097/HCO.0000000000000440. Review.


Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review.

Elliott J, Kelly SE, Bai Z, Liu W, Skidmore B, Boucher M, So DY, Wells GA.

BMJ Open. 2017 Apr 4;7(4):e015421. doi: 10.1136/bmjopen-2016-015421. Review.


Impact of mean arterial pressure on clinical outcomes in comatose survivors of out-of-hospital cardiac arrest: Insights from the University of Ottawa Heart Institute Regional Cardiac Arrest Registry (CAPITAL-CARe).

Russo JJ, James TE, Hibbert B, Yousef A, Osborne C, Wells GA, Froeschl MP, So DY, Chong AY, Labinaz M, Glover CA, Marquis JF, Dick A, Bernick J, Le May MR.

Resuscitation. 2017 Apr;113:27-32. doi: 10.1016/j.resuscitation.2017.01.007. Epub 2017 Jan 18.


A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.

Pourdjabbar A, Hibbert B, Chong AY, Le May MR, Labinaz M, Simard T, Ramirez FD, Lugomirski P, Maze R, Froeschl M, Glover C, Dick A, Marquis JF, Bernick J, Wells G, So DY; CAPITAL Investigators.

Thromb Haemost. 2017 Jan 26;117(2):303-310. doi: 10.1160/TH16-04-0340. Epub 2016 Oct 20.


Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System.

Rashid MK, Guron N, Bernick J, Wells GA, Blondeau M, Chong AY, Dick A, Froeschl MP, Glover CA, Hibbert B, Labinaz M, Marquis JF, Osborne C, So DY, Le May MR.

JACC Cardiovasc Interv. 2016 Oct 10;9(19):2014-2020. doi: 10.1016/j.jcin.2016.07.004.


Reply: The Conundrum of Allen's Test Before Transradial Access: To Do or Not to Do?

Singh K, Chong AY, So DY.

JACC Cardiovasc Interv. 2016 May 9;9(9):981. doi: 10.1016/j.jcin.2016.02.043. No abstract available.


A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes.

Pourdjabbar A, Hibbert B, Chong AY, Abunassar J, Malhotra N, Whitten TA, Le May MR, So DY; CAPITAL investigators.

Int J Cardiol. 2016 Jul 1;214:423-5. doi: 10.1016/j.ijcard.2016.03.153. Epub 2016 Mar 24. No abstract available.


Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents.

Di Santo P, Simard T, Ramirez FD, Pourdjabbar A, Harnett DT, Singh K, Moreland R, Chong AY, Dick A, Labinaz M, Froeschl M, Froeschl M, Le May MR, So DY, Hibbert B.

Clin Invest Med. 2015 Oct 7;38(5):E296-304.


Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.

Fu A, Singh K, Abunassar J, Malhotra N, Le May M, Labinaz M, Glover C, Marquis JF, Froeschl M, Dick A, Hibbert B, Chong AY, So DY; CAPITAL Investigators.

Clin Cardiol. 2016 Jan;39(1):19-23. doi: 10.1002/clc.22486. Epub 2016 Jan 8.


Digital Gangrene Following Transradial Coronary Angiogram.

Singh K, Abunassar J, So DY.

JACC Cardiovasc Interv. 2016 Jan 25;9(2):e21-2. doi: 10.1016/j.jcin.2015.10.033. Epub 2015 Dec 23. No abstract available.


Safety and Efficacy of Staged Percutaneous Coronary Intervention During Index Admission for ST-Elevation Myocardial Infarction With Multivessel Coronary Disease (Insights from the University of Ottawa Heart Institute STEMI Registry).

Russo JJ, Wells GA, Chong AY, So DY, Glover CA, Froeschl MP, Hibbert B, Marquis JF, Dick A, Blondeau M, Bernick J, Labinaz M, Le May MR; CAPITAL Investigators.

Am J Cardiol. 2015 Oct 15;116(8):1157-62. doi: 10.1016/j.amjcard.2015.07.029. Epub 2015 Jul 29.


Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?

Knauer MJ, Diamandis EP, Hulot JS, Kim RB, So DY.

Clin Chem. 2015 Oct;61(10):1235-40. doi: 10.1373/clinchem.2015.238105. Epub 2015 Aug 13. No abstract available.


Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?

Qutub MA, Chong AY, So DY.

Can J Cardiol. 2015 Dec;31(12):1481-4. doi: 10.1016/j.cjca.2015.04.019. Epub 2015 Apr 28. Review.


A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window.

Malhotra N, Abunassar J, Wells GA, McPherson R, Fu A, Hibbert B, Labinaz M, Le May M, Dick A, Glover C, Froeschl M, Marquis JF, Tran L, Bernick J, Chong AY, So DY; CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators.

Int J Cardiol. 2015 Oct 15;197:318-25. doi: 10.1016/j.ijcard.2015.06.016. Epub 2015 Jun 15.


Supplemental Content

Support Center